<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Regenxbio Inc — News on 6ix</title>
    <link>https://6ix.com/company/regenxbio-inc</link>
    <description>Latest news and press releases for Regenxbio Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 11 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/regenxbio-inc" rel="self" type="application/rss+xml" />
    <item>
      <title>REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-reports-new-positive-interim-data-from-phase-iii-affinity-duchenner-trial-of-rgx-202</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-reports-new-positive-interim-data-from-phase-iii-affinity-duchenner-trial-of-rgx-202</guid>
      <pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
      <description>Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne Pivotal dose participants exceeded external</description>
    </item>
    <item>
      <title>REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights-12</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights-12</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at</description>
    </item>
    <item>
      <title>REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-presentations-at-the-2026-muscular-dystrophy-association-mda-clinical-and-scientific-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-presentations-at-the-2026-muscular-dystrophy-association-mda-clinical-and-scientific-conference</guid>
      <pubDate>Wed, 04 Mar 2026 12:05:00 GMT</pubDate>
      <description>REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations on its RGX-202 investigational gene therapy for Duchenne muscular dystrophy at the 2026 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference, taking place in Orlando, FL March 8-11, 2026.</description>
    </item>
    <item>
      <title>REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-to-host-conference-call-on-march-5-to-discuss-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-to-host-conference-call-on-march-5-to-discuss-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights</guid>
      <pubDate>Wed, 25 Feb 2026 12:05:00 GMT</pubDate>
      <description>REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.</description>
    </item>
    <item>
      <title>REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-regulatory-rgx-121-210500604</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-regulatory-rgx-121-210500604</guid>
      <pubDate>Mon, 09 Feb 2026 21:05:00 GMT</pubDate>
      <description>REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for RGX-121 (clemidsogene lanparvovec) for the treatment of Mucopolysaccharidosis II (MPS II), an ultra-rare neurodegenerative disease also known as Hunter syndrome.</description>
    </item>
    <item>
      <title>REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-regulatory-ultra-rare-123000133</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-regulatory-ultra-rare-123000133</guid>
      <pubDate>Wed, 28 Jan 2026 12:30:00 GMT</pubDate>
      <description>REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study. The FDA also placed a clinical hold on RGX-121, for the treatment of MPS II, also known as Hunter Syndrome, citing the similarities in pro</description>
    </item>
    <item>
      <title>REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-highlights-key-2026-catalysts-and-announces-positive-long-term-functional</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-highlights-key-2026-catalysts-and-announces-positive-long-term-functional</guid>
      <pubDate>Sun, 11 Jan 2026 05:00:00 GMT</pubDate>
      <description>New Phase I/II RGX-202 functional data demonstrates long-term, durable treatment effect at pivotal dose at 18 months Robust patient enrollment in confirmatory</description>
    </item>
    <item>
      <title>REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-present-44th-annual-jp-morgan-healthcare-conference-2025-12-18</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-present-44th-annual-jp-morgan-healthcare-conference-2025-12-18</guid>
      <pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md., Dec. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44th Annual J.P. Morgan Healthcare</description>
    </item>
    <item>
      <title>REGENXBIO to Participate in Upcoming Investor Conference</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-participate-upcoming-investor-conference-2025-11-25</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-participate-upcoming-investor-conference-2025-11-25</guid>
      <pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md., Nov. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conference:Piper</description>
    </item>
    <item>
      <title>REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-reports-third-quarter-2025-financial-results-and-operational-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-reports-third-quarter-2025-financial-results-and-operational-highlights</guid>
      <pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
      <description>RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial</description>
    </item>
    <item>
      <title>REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-completion-pivotal-enrollment-and-initiates-commercial-production</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-completion-pivotal-enrollment-and-initiates-commercial-production</guid>
      <pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
      <description>Patients treated with RGX-202 demonstrate consistent, robust microdystrophin expression and functional improvement compared to natural history in Phase I/II</description>
    </item>
    <item>
      <title>REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-host-conference-call-november-6-discuss-third-quarter-2025-financial</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-host-conference-call-november-6-discuss-third-quarter-2025-financial</guid>
      <pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md., Oct. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 6, at</description>
    </item>
    <item>
      <title>REGENXBIO to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-participate-upcoming-investor-conferences-2025-10-15</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-participate-upcoming-investor-conferences-2025-10-15</guid>
      <pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md., Oct. 15, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:</description>
    </item>
    <item>
      <title>REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-presentation-american-academy-ophthalmology-2025-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-presentation-american-academy-ophthalmology-2025-annual-meeting</guid>
      <pubDate>Thu, 09 Oct 2025 04:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md., Oct. 9, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present interim data from the Phase II ALTITUDE®</description>
    </item>
    <item>
      <title>REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-completion-enrollment-pivotal-trials-subretinal-surabgene</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-completion-enrollment-pivotal-trials-subretinal-surabgene</guid>
      <pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
      <description>Over 1,200 participants enrolled in ATMOSPHERE® and ASCENT® pivotal trials, representing largest global gene therapy program ever conducted Subretinal</description>
    </item>
    <item>
      <title>REGENXBIO Announces Presentation at the World Muscle Society</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-presentation-world-muscle-society-2025-09-29</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-presentation-world-muscle-society-2025-09-29</guid>
      <pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md., Sept. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced Chief Medical Officer, Steve Pakola, M.D., will present at the</description>
    </item>
    <item>
      <title>REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-presents-positive-twelve-month-pivotal-data-phase-i-ii-iii-campsiiter-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-presents-positive-twelve-month-pivotal-data-phase-i-ii-iii-campsiiter-trial</guid>
      <pubDate>Fri, 05 Sep 2025 04:00:00 GMT</pubDate>
      <description>12-month pivotal data further demonstrate the ability of one-time RGX-121 treatment to improve outcomes for patients with MPS II&gt;80% reduction in CSF levels</description>
    </item>
    <item>
      <title>REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-fda-review-extension-bla-rgx-121-treat-patients-mps-ii-2025-08-18</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-fda-review-extension-bla-rgx-121-treat-patients-mps-ii-2025-08-18</guid>
      <pubDate>Mon, 18 Aug 2025 04:00:00 GMT</pubDate>
      <description>RGX-121 would be the first and only potential one-time commercially-available therapy designed to directly address the underlying genetic cause of Hunter</description>
    </item>
    <item>
      <title>REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-reports-second-quarter-2025-financial-results-and-operational-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-reports-second-quarter-2025-financial-results-and-operational-highlights</guid>
      <pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
      <description>RGX-202 in Duchenne muscular dystrophy on track for topline results 1H 2026 and BLA submission mid-2026Pivotal trial enrollment accelerated, expected to</description>
    </item>
    <item>
      <title>REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy</title>
      <link>https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-pivotal-program-surabgene-lomparvovec-diabetic-retinopathy-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/regenxbio-inc/news/regenxbio-announces-pivotal-program-surabgene-lomparvovec-diabetic-retinopathy-2025</guid>
      <pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
      <description>A pivotal Phase IIb/III clinical trial using suprachoroidal delivery for treatment of diabetic retinopathy will be initiatedNew Phase II ALTITUDE® trial data</description>
    </item>
  </channel>
</rss>